Coherus BioSciences, a clinical-stage biologics platform company focused on the emerging biosimilars market, raised $85 million by offering 6.3 million shares at $13.50, the midpoint of the range of $12 to $15. Insiders planned to buy $35 million on the IPO. Coherus BioSciences plans to list on the NASDAQ under the symbol CHRS. Coherus BioSciences initially filed confidentially on 8/4/2014. J.P. Morgan and Credit Suisse acted as lead managers on the deal.
